국내 소재 글로벌 제약사의 연구개발 규모 및 현황

• 영문명: The R&D Scale and Status of Global Pharmaceutical Companies in Korea: Survey for 5 years from 2016 to 2020
• 발행기관: 대한약학회
• 저자명: 오인선(In-Sun Oh) 조혜원(Hye Won Cho) 이현주(Hyun Joo Lee) 송혜원(Hye Won Song) 한나래(Na Rae Han) 김초롱(Cho Rong Kim) 임혜인(Hye In Lim) 신주영(Ju-Young Shin)
• 간행물 정보: 『약학회지』제65권 6호, 494~501쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2021.12.31

영문 초록

While the importance of the global pharmaceutical industry is growing owing to continued new drug developments and R&D investments, the scale of global pharmaceutical companies in Korea remains unclear. We therefore investigated the R&D status of global pharmaceutical companies in Korea through an annual survey from 2016 to 2020. We assessed five factors annually and their trend over the 5-year period: costs, personnel, number of clinical trials, number of clinical trial subjects, and others. We then examined the correlation among factors and further compared the trend between each factor and the gross domestic product (GDP). Of 35 companies that responded, 25 responded for five consecutive years and showed a steady increase in the cost, personnel, and the number of clinical trials. While costs and personnel increased more than the GDP over the 5-year period, the number of clinical trials remained similar; number of clinical trial subjects highly fluctuated year-by-year. Moreover, a high correlation was found for cost and personnel (r>0.8852), and cost and the number of clinical trials (r>0.8452). In conclusion, costs, personnel, and the number of clinical trials of global pharmaceutical companies in Korea steadily increased from 2016 to 2020 and thus, have continuously contributed to the domestic economy.

목차

서 론(Introduction)

방 법(Methods)

결 과(Results)

고 찰(Discussion)

결 론(Conclusion)

References

키워드

Global pharmaceutical companies Survey Research and development Cost